in vitro asthma models

Additional Info

  • Overview:

    Asthma Grant

    Title                    

    Asthma                                                                 

    Co-ordinator Cellix Ltd
    Partners School of Medicine, University of Aberdeen, Aberdeen, Scotland
    Funding  Body EU Commission
    Grant Type Marie Curie Fellowship Industry Academia Partnership (FP6)*
    Date 4th April 2006 – 4th April 2009
    Abstract The Academic partner is the Allergic & Asthmatic Inflammation group, School of Medicine, University of Aberdeen (UNIABDN) whose work focuses on the cells and mediators responsible for the initiation and resolution of inflammation in asthmatic and allergic disease. Asthma is now the most common chronic disease in westernised countries. It is a complex syndrome characterised by a variable degree of airway obstruction in which the fundamental abnormality is airway inflammation. 

    One key area of ongoing work is furthering understanding of how an important pro-inflammatory effector cell in asthma, the eosinophil, selectively accumulates in the asthmatic lung. Central to this is an understanding of how eosinophils transmigrate from the blood vessels of the lung into the surrounding tissues when they exert their pro-inflammatory effects. This project combines proven expertise in leukocyte adhesion and transmigration (UNIABDN) with expertise in microflow adhesion of high throughput assays (Cellix). The development of the resulting platform technology will be used to identify therapeutic targets for asthma and to apply these novel technologies to other human diseases with a significant inflammatory component. 

    By identifying those immunomodulators that facilitate/block adhesion and transmigration processes in an in vitro setting prior to using an animal model, pharmaceutical companies would be able to remove/include such compounds from down-stream processing, thereby eliminating false leads earlier reducing the drug development cycle and cost. The new area of competence to be developed will require a multi disciplinary effort and this is one of the key benefits of the ToK approach.
    Equipment
    Results Respiratory: eosinophil; adhesion assay; asthma (NL)
    Keywords asthma, migration, VLA-4
    Contact This email address is being protected from spambots. You need JavaScript enabled to view it. or phone +353-1-4500-155

    *The Marie Curie Fellowship Industry Academia Partnership funding is available for universities, research organisations, and businesses in the EU or Associated States to provide early-stage researchers of any nationality or age with structured scientific or technological training opportunities of between three months to three years.

  • Recommended Products:

    Microfluidic Biochips

    Vena8 Fluoro+
    The Vena8 Fluoro+™ biochip is ideal for rolling and...

    Vena8 Endothelial+
    The Vena8 Endothelial+™ biochip is ideal for cell-cell...

    VenaT4 - chemotaxis, transmigration & invasion assays
    The VenaT4™ biochip for chemotaxis, transmigration and...

    Microfluidic Pumps

    Mirus Evo Nanopump - PC controlled
    The Mirus™ Evo Nanopump is a microfluidic syringe pump PC...

    Kima - iPod Touch Microfluidic Pump
    The Kima™ pump is a microfluidic recirculating pump...

    ExiGo - iPad mini or LabVIEW controlled Microfluidic Pump
    The ExiGo™ pump is a microfluidic syringe pump controlled...